Hill Claudia A P, Bau Luca, Carlisle Robert
Institute of Biomedical Engineering, University of Oxford, Oxford, UK.
Methods Mol Biol. 2020;2058:7-29. doi: 10.1007/978-1-4939-9794-7_2.
The optimal clinical exploitation of viruses as gene therapy or oncolytic vectors will require them to be administered intravenously. Strategies must therefore be deployed to enable viruses to survive the harsh neutralizing environment of the bloodstream and achieve deposition within and throughout target tissues or tumor deposits. This chapter describes the genetic and chemical engineering approaches that are being developed to overcome these challenges.
将病毒作为基因治疗或溶瘤载体进行最佳临床应用需要通过静脉注射给药。因此，必须采用相应策略，使病毒能够在血流的恶劣中和环境中存活，并在整个靶组织或肿瘤灶内实现沉积。本章介绍了为克服这些挑战而正在研发的基因工程和化学工程方法。
